https://www.selleckchem.com/pr....oducts/bsj-4-116.htm
1, 4.2, p 0.001), 28 mOsm/L for osmolarity (95% CI 23.6, 32.4, p 0.001) and 0.03 mm for meniscus height (95% CI 0.02, 0.04, p 0.001). No adverse effects were observed. IPL/LLLT is safe and produces an important reduction in symptoms and signs of dry eye disease, still relevant one year after the end of treatment in a sample with high symptoms' severity. Therefore, it represents a promising treatment option for patients who do not improve with conventional treatment. Randomized trials are needed to determine the added benef
Like
Comment
Share
